Zenith Contract Services

Global Crossing Airlines Announces Glen Gates as Vice President - A321 Freighter Programs

Retrieved on: 
Monday, January 9, 2023
Zenith Contract Services, Transport, CMI, NEO, Active, ACMI, Postal, Chair, Technology College, A321, Midway Airlines, JET, Hyperloop Transportation Technologies, National Airlines (N8), DHL Aviation, Airline

MIAMI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the “Company” or “GlobalX”) is pleased to announce the appointment of Mr. Glen Gates as Vice President - A321 Freighter Programs.

Key Points: 
  • MIAMI, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the “Company” or “GlobalX”) is pleased to announce the appointment of Mr. Glen Gates as Vice President - A321 Freighter Programs.
  • Mr. Gates brings over 38 years of creating and managing profitable freighter revenue programs.
  • “We are delighted Glen is joining us at GlobalX as we prepare to take delivery of our first two A321 freighters.
  • “I am excited to join GlobalX and build our ad hoc charter business with the A321 freighter, the best in class narrowbody freighter,” said Glen Gates, Vice President - A321 Freighter Programs.

FlatTech LLC Receives Innovative Technology Contract from Vizient for EpiFaith(R) Syringe for safer epidurals

Retrieved on: 
Monday, January 9, 2023
Syringe, Academic health science centre, The Queen's Award for Enterprise: Innovation (Technology) (2011), Medtech, Risk, Zenith Contract Services, BMI, Patient, Safety, Uncertainty, Epidural space, Patient safety, Medicine, Pharmaceutical industry, Medical device, Vizient, Inc.

TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith® Syringe for epidural has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. The contract was awarded based on the recommendation of EpiFaith® by hospital experts who serve on one of Vizient's member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the health care industry.

Key Points: 
  • TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith® Syringe for epidural has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program.
  • Through its Innovative Technology Program , Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to health care.
  • Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

Biologics Fill Finish Services Markets, 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Pharmaceutical, Health, Biometrics, Chief, Syringe, Risk, Zenith Contract Services, Growth, Business development, Type, International business development, Safety, Health, Biocon, Fine chemical, Borosilicate glass, Risk management, Cassette tape, Management

Biologics Fill / Finish Services Market Industry Trends and Global Forecasts report features an extensive study on the biologics fill / finish service providers.

Key Points: 
  • Biologics Fill / Finish Services Market Industry Trends and Global Forecasts report features an extensive study on the biologics fill / finish service providers.
  • With the growing pipeline of biologics, the demand for contract services for biologics development and biologics fill / finish has increased.
  • What is the current demand for biologics fill / finish services?
  • What is the current and future market size for biologics fill / finish services?

KARL STORZ Receives Innovative Technology Designation from Vizient for TIPCAM1 Rubina with ARTip SOLO Robotic Assistance

Retrieved on: 
Friday, December 23, 2022
Oncology, Software, Medical Devices, Hardware, Hospitals, Data Management, Technology, Practice Management, Veterinary, Nursing, Managed Care, Medical Supplies, Cardiology, General Health, Surgery, Robotics, Health, Health Technology, Surgeon, Patient safety, Karl Storz SE, The Chartered Institute of Ergonomics and Human Factors, ONE, Environment, The Queen's Award for Enterprise: Innovation (Technology) (2011), Artipic, Robotics, Academic health science centre, Safety, MD, Health, Multimedia, KARL, Laparoscopy, 3D, Workflow, Hospital, Zenith Contract Services, Pharmaceutical industry, Medical imaging, Medicine, Medical device, Vizient, Inc., Oncology, Software, Medical Devices, Hardware, Hospitals, Data Management, Technology, Practice Management, Veterinary, Nursing, Managed Care, Medical Supplies, Cardiology, General Health, Surgery, Robotics, Health, Health Technology

KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc. , the largest healthcare performance improvement company in the country.

Key Points: 
  • KARL STORZ Endoscopy-America, Inc., proudly announces its TIPCAM®1 Rubina® with ARTip® SOLO robotic assistance has received an Innovative Technology designation from Vizient, Inc. , the largest healthcare performance improvement company in the country.
  • KARL STORZ exhibited TIPCAM1 Rubina with ARTip SOLO at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas, Texas.
  • The ARTip® SOLO robotic camera guidance system allows the operating surgeon to maintain stability and precise control of the field of view.
  • Congratulations to KARL STORZ.”
    For more detailed information, about TIPCAM®1 Rubina® and ARTip® SOLO technology, visit karlstorznetwork1.com .

re:3D Releases UltiMachine ArchiMajor 32bit PCB in New Gigabot & Terabot 3D Printers to Boost Supply Chain Resiliency

Retrieved on: 
Sunday, January 1, 2023
PCB, Catalysis, 3D printing, Multimedia, Electronics, 3D, Zenith Contract Services, Video game console, Klipper

Not only does this board increase Gigabot & Terabot processing power, but it supports better control of re:3D's supply chain and electronics quality with a strong US manufacturing partner.

Key Points: 
  • Not only does this board increase Gigabot & Terabot processing power, but it supports better control of re:3D's supply chain and electronics quality with a strong US manufacturing partner.
  • "Installing the UltiMachine ArchiMajor 32bit PCB was a critical evolution in the Gigabot & Gigabot X portfolio," says re:3D Co-founder and Catalyst, Samantha Snabes.
  • Beyond creating 3D printers for customers in over 50 countries, re:3D offers 3D printing contract services, consulting, design and education services.
  • UltiMachine is a leading 3D Printer component manufacturer who develops systems that drive additive manufacturing, specializing in electronics and consumables.

Extendicare Announces December 2022 Dividend of C$0.04 per Share

Retrieved on: 
Thursday, December 15, 2022
Health, Bed, Disclosure, Income Tax Act, Section 50C of the Isle of Man Income Tax Act 1970, TSX, Zenith Contract Services, Retirement, Health insurance, Extendicare

MARKHAM, Ontario, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of December 2022, which is payable on January 16, 2023 to shareholders of record at the close of business on December 30, 2022.

Key Points: 
  • MARKHAM, Ontario, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of December 2022, which is payable on January 16, 2023 to shareholders of record at the close of business on December 30, 2022.
  • This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).
  • Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands.
  • Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare’s website at www.extendicare.com.

Umano Medical Receives Innovative Technology Designation from Vizient for the ook snow ALL with Pilot Drive

Retrieved on: 
Thursday, December 1, 2022
ALL, Academic health science centre, Patient safety, Health, Patient, Zenith Contract Services, The Queen's Award for Enterprise: Innovation (Technology) (2011), Snow, Safety, Pharmaceutical industry, Vizient, Inc.

Umano Medical exhibited the ook snow ALL with Pilot Drive at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas.

Key Points: 
  • Umano Medical exhibited the ook snow ALL with Pilot Drive at the Vizient Innovative Technology Exchange on Oct. 17 in Dallas.
  • The Pilot Drive adds mobility, patient safety and product performance without compromise to Umano Medical's most versatile bed, the ook snow ALL.
  • The ook snow ALL with Pilot Drive offers game-changing standardization possibilities throughout all care settings, including bariatric, med-surgical, and palliative care units.
  • Sales, Umano Medical
    "Congratulations to Umano Medical for achieving this peer-designated status," said Kelly Flaharty, Vizient senior director of contract services.

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Retrieved on: 
Tuesday, November 22, 2022
CAR, Cancer, University, Mouse, Security (finance), IQV, Privacy, Investigational New Drug, Therapy, NYSE, Drug discovery, Patient, Government, COVID-19, Risk, Regulatory affairs, Zenith Contract Services, IND, Neoplasm, Food, Regulation of tobacco by the U.S. Food and Drug Administration, Intelligence, Pharmaceutical industry, Vaccine, IQVIA

WEXFORD, Pa., Nov. 22, 2022 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)  ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced an agreement with IQVIA, a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, to support the development of SNAP-CAR, a multi-antigen chimeric antigen receptor T cell (CAR T) technology that Coeptis licensed from the University of Pittsburgh.  SNAP-CAR is designed as a "universal" CAR T cell therapy platform that can be adapted to different cancer indications, including hematologic and solid tumors.

Key Points: 
  • Under the terms of the agreement, IQVIA will collaborate with Coeptis to prioritize the target indications for the SNAP-CAR program and manage activities designed to enable the filing of an Investigational New Drug (IND) application.
  • "Given this tremendous opportunity, Coeptis is now moving full-force to initiate a first-in-human clinical program to investigate SNAP-CAR, and we are excited to partner IQVIA to begin the development process.
  • Michael Kardas, VP of Regulatory Affairs and Drug Discovery Solutions at IQVIA, stated, "We are pleased to have this opportunity to collaborate with Coeptis to advance the development of SNAP-CAR.
  • Coeptis was founded in 2017 and is headquartered inWexford, PA. For more information on Coeptis visit https://coeptistx.com/ .

KULR Technology Group Reports Record Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
SAN, GLOBE, COO, Cloud computing, Platinum, General officer, Forward-looking statement, Marketing, Investment, NYSE, U.S. Securities and Exchange Commission, Research and development, Advertising, Risk, Department, SG, Technology, Database, Efficiency, Holocene, R, Department of Defence, Solution, Safety, Association, Time, Federal Aviation Administration, Contract, CFO, Company, Form 10-K, Research, Transport, Conference, Growth, Algorithm, KULR, Administration, Security (finance), Rail transport by country, Lockheed Martin, Acquisition, Zenith Contract Services, Video game, Renewable energy, Risk management

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the third quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today reported results for the third quarter ended September 30, 2022.
  • Gross Margins: Gross margin was 33% in the quarter ended September 30, 2022, compared to 74% in the same period last year.
  • The third quarter was an inflection point for KULR as we achieved record revenue results and began transitioning to the next chapter of our growth story, said KULR CEO Michael Mo.
  • About KULR Technology Group Inc.
    KULR Technology Group Inc. (NYSE American: KULR) is a leading energy management platform offering proven solutions that play a critical role in accelerating the electrification of the circular economy.

Linear Health Sciences Receives Innovative Technology Contract from Vizient for Orchid SRV IV Safety Device

Retrieved on: 
Tuesday, November 8, 2022
Medical Devices, Health, Review, Abscess, Technology, COO, Patient, Patient safety, Orchidaceae, Academic health science centre, The Queen's Award for Enterprise: Innovation (Technology) (2008), Confusion, Zenith Contract Services, Hospital, Caregiver, Drainage, Outline of health sciences, Safety, Risk, Medicine, Pharmaceutical industry, Medical device, Vizient, Inc.

Linear Health Sciences today announced its Orchid SRV tension-activated breakaway safety release valve received an Innovative Technology contract from Vizient, Inc. , the nations largest member-driven healthcare performance improvement company.

Key Points: 
  • Linear Health Sciences today announced its Orchid SRV tension-activated breakaway safety release valve received an Innovative Technology contract from Vizient, Inc. , the nations largest member-driven healthcare performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizients Innovative Technology Program.
  • Clinical simulation testing of 360 Orchid SRVs showed that the device prevented IV dislodgement by 91.9 percent across all test groups.
  • Our member council determined that Linear Health Science's Orchid SRV met this standard and recognizes its potential to improve quality outcomes.